News Hub

Members in the News: Minaris Regenerative Medicine

  
Members in the News: Minaris Regenerative Medicine




Minaris Regenerative Medicine GmbH and Mendus AB extend manufacturing partnership to large-scale production of DCP-001, an experimental allogeneic cell-based immunotherapy addressing tumor recurrence

Munich, Germany, and Stockholm, Sweden - Oct 28, 2022. Mendus AB (“Mendus publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence and Minaris Regenerative Medicine GmbH („Minaris“), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have extended their manufacturing partnership for technology transfer as well as clinical and potentially commercial manufacture of DCP-001, Mendus’ lead cancer immunotherapy development program currently being evaluated in clinical trials. Minaris and Mendus had entered into a manufacturing agreement for clinical supply in November 2018.

Minaris will perform technology transfer and manufacture of a new large-scale process developed by Mendus at its facilities in Ottobrunn near Munich, Germany. DCP-001 is an allogeneic, off-the-shelf cancer relapse vaccine currently evaluated in the ADVANCE II phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON phase 1 clinical trial in ovarian cancer.

“We are delighted to continue this long-standing and productive partnership and to support Mendus with the large-scale industrial manufacturing of their innovative therapy to address the unmet medical need of cancer relapse,” said Dusan Kosijer, CEO of Minaris.
“Considering the encouraging data reported so far for DCP-001, it is time to prepare for the transition into late-stage manufacturing infrastructure and to transfer our large-scale industrial manufacturing process to an experienced manufacturing partner”, commented Leopold Bertea, PhD, Chief Technology Officer of Mendus. “We have chosen Minaris as our CDMO and manufacturing partner in consideration of their demonstrated outstanding abilities and track-record, and their focus on the production of cell and gene therapy products.”

Access the full press release here.
This press release was written and distributed by Minaris.
For all enquiries, please contact Minaris directly.


#IndustryMemberNews
#29.11
0 comments
5 views

Permalink